MRK Stock Research, Signals & Filings

Drillr aggregates AI research, SEC filings, earnings signals, alt-data and financial tables for MRK. 5 published articles.

Latest Research

  1. LLY: $2.3B Ajax Buy Hedges Mounjaro Patent Cliff

    Eli Lilly's $2.3 billion Ajax Therapeutics acquisition reveals a critical divergence in large-cap pharma M&A strategy that the market has mispriced. While Merck and Pfizer scramble to replace patent cliff revenue with expensive blockbuster acquisitions, Lilly is buying rare-disease optionality from a position of GLP-1 strength. Long LLY versus short MRK/PFE targets 8-12% relative return over six months as earnings reveal the cost of desperate dealmaking.

    LLYPFEBMY

  2. Pharma Tariffs: Buy LLY & AMGN, Sell PFE & MRK — Here's Why

    Trump policies eroding Europe's pharma lead via tariffs favor US manufacturing-heavy Eli Lilly and Amgen, with strong growth and margins, while Pfizer and Merck's global chains invite cost squeezes. J&J and AbbVie sit in the middle with diversification. Rank: Buy LLY/AMGN, sell PFE/MRK.

    LLYAMGNABBV

  3. Trump 100% Pharma Tariffs: PFE and MRK Face $200M Hit While LLY Gains 25%

    Trump's proposed 100% pharma tariffs and China's biotech surge, per April 11 CNBC, threaten Europe's manufacturing edge, hiking costs for PFE (-2.8% 1M) and MRK (-5.1% 1M) while LLY's US focus drives 25% 2026 growth. Supply chain filings flag $100-200M hits; investors should fade exposed names, buy domestic leaders. Next catalysts: Earnings tariff disclosures and China trade flows.

    PFELLYTMO

  4. Pharma Tariffs: LLY and AMGN Win While PFE and MRK Face Margin Squeeze

    Trump's pharma import tariffs shield U.S.-focused drugmakers like Eli Lilly and Amgen from cost hikes while pressuring import-reliant Pfizer and Merck. Analysis ranks six majors by exposure, highlighting financials and guidance. Domestic winners eye margin expansion amid onshoring push.

    LLYAMGNABBV

  5. Pharma Tariffs: LLY, TMO, CVS Supply Chain Exposure Ranked by Risk

    Trump's April 2 pharma tariff announcement highlights supply chain risks for LLY, TMO, and CVS, with SEC filings exposing China reliance. Stocks dipped mildly, but domestic manufacturing offers protection amid margin pressures.

    PFELLYTMO

Track MRK with Drillr

SEC filings, earnings calls, alt-data signals — all queryable through Drillr's AI terminal and MCP API.

Try drillr.ai for free